Valaris VAL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1B+2.2% | $979.1M+149% | $392.9M+46.3% | $268.5M-12.0% | $305.1M-17.5% | ||
| $26M+3.2% | $25.2M+6.3% | $23.7M-0.8% | $23.9M-5.5% | $25.3M-8.7% | ||
| -$675.4M-31.1% | -$515.1M— | —— | —— | —— | ||
| $89.9M-24.2% | $118.6M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$22.8M+44.4% | -$41M+28.7% | -$57.5M— | —— | —— | ||
| $12.6M+50.0% | $8.4M— | —— | —— | —— | ||
| $14.9M-10.2% | $16.6M+10.7% | $15M-36.7% | $23.7M-1.7% | $24.1M+12.1% | ||
| $465.3M-14.8% | $546.2M-8.8% | $598.6M+0.9% | $593.5M+22.4% | $485M+36.5% | ||
| $344.2M+0.2% | $343.5M-1.5% | $348.9M-3.4% | $361M-10.6% | $404M-11.2% | ||
| $125.3M-9.1% | $137.9M-0.7% | $138.9M+358% | $30.3M+47.1% | $20.6M+636% | ||
| —— | —— | —— | -$330.7M+13.7% | -$383.4M+15.2% | ||
| —— | —— | —— | —— | —— | ||
| -$104.7M-1.1% | -$103.6M+1.6% | -$105.3M+32.9% | -$156.9M+0.1% | -$157M+0.8% | ||
| —— | —— | $283.3M+168% | $105.9M+291% | -$55.4M+78.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $146.3M+4.3% | $140.25M+4.5% | $134.2M+4.7% | $128.15M+5.0% | ||
| $89.9M-24.2% | $118.6M— | —— | —— | —— | ||
| $12.6M+50.0% | $8.4M— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.15M+15.0% | ||
| $6.5M+140% | -$16.1M-1.9% | -$15.8M+64.4% | -$44.4M-20.3% | -$36.9M+6.1% | ||
| -$6.5M+18.8% | -$8M0.0% | -$8M-12.7% | -$7.1M+4.1% | -$7.4M-7.2% | ||
| $14.9M-10.2% | $16.6M+10.7% | $15M-36.7% | $23.7M-1.7% | $24.1M+12.1% | ||
| $125.3M-9.1% | $137.9M-0.7% | $138.9M+358% | $30.3M+47.1% | $20.6M+636% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Valaris's cash flow data come from?
- Every line is extracted from Valaris's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.